Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229)

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 5, 1998, Pages 1039-1047

  Thomas Jr , Charles R ^a,g   Giroux, Dori J ^b   Stelzer, Keith J ^a   Craig, Johnny B ^c   Laufman, Leslie R ^d   Taylor, Sarah A ^e   Goodwin, John W ^f   Crowley, John J ^b   Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Columbus CCOP ^*  (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f Ozarks Regional CCOP   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chest and brain irradiation; Cisplatin; Oral etoposide; SCLC; Vincristine

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0032520999     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00003-0     Document Type: Article

References (49)

1. Kies M. S., Mira J. G., Crowley J. J., et al. Multimodal therapy for limited small-cell lung cancer A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field vs. reduced field radiation in partial responders: A Southwest Oncology Group study . J. Clin. Oncol. 5:1987;592-600.
2. Bunn P. A., Lichter A. S., Makuch R. W., et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective randomized trial. Ann. Intern. Med. 106:1987;655-662.
3. McCracken J. D., Janaki L. M., Crowley J. J., et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma A Southwest Oncology Group study . J. Clin. Oncol. 8:1990;892-898.
4. Johnson B. E., Grayson J., Makuch R. W., et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J. Clin. Oncol. 8:1990;396-401.
5. Murray N., Coy P. I., Pater J. L., et al. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 11:1993;336-344.
6. Bunn P. A. Jr, Crowley J., Kelly K., et al. Chemoradiotherapy with or wihout granulocyte-macrophage colony-stimulating factor in the treatment of limited stage small-cell lung cancer A prospective phase III randomized study of the Southwest Oncology Group . J. Clin. Oncol. 13:1995;1632-1641.
7. Slevin M. L., Clark P. I., Joel S. P., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7:1989;1333-1340.
8. Mead G. M., Thompson J., Sweetenham J. W., et al. Extensive stage small cell carcinoma of the bronchus. A randomized study of etoposide given orally by one-day or five-day schedule together with intravenous Adriamycin and cyclophosphamide. Cancer Chemother. Pharmacol. 19:1987;172-174.
9. Jackson D. V. Jr, Case L. D., Zekan P. J., et al. Improvement of long-term survival in extensive small-cell lung cancer. J. Clin. Oncol. 6:1988;1161-1169.
10. Abratt R. P., Willcox P. A., de Groot M., et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur. J. Cancer. 27:1991;28-30.
11. Johnson D. H., Greco F. A., Strupp J., et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer A phase II trial . J. Clin. Oncol. 10:1990;1613-1617.
12. Johnson D. H., Hainsworth J. D., Hande K. R., et al. Current status of etoposide in the management of small cell lung cancer. Cancer. 67:1991;231-244.
13. Murphy P. B., Hainsworth J. D., Greco F. A., et al. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer. 69:1992;370-375.
14. Livingston R. B., Crowley J. J., Thompson T., et al. Prolonged, alternating chemotherapy for extensive small cell lung cancer A Southwest Oncology Group study . Cancer. 71:1993;3509-3513.
15. Evans W. K., Shepherd F. A., Feld R., et al. VP-16 and cisplatin as first-line therapy for small cell cancer. J. Clin. Oncol. 3:1985;1471-1477.
16. Einhorn L. H., Crawford J., Birch R., et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J. Clin. Oncol. 6:1988;451-456.
17. Shepherd F. A., Evans W. K., MacCormick R., et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat. Rep. 71:1987;941-944.
18. Campling B., Quirt I., DeBoer G., et al. Is bone marrow examination in small-cell lung cancer really necessary? Ann. Intern. Med. 105:1986;508.
19. Humblet Y., Syman M. Detection of small-cell lung cancr bone marrow metastasis by tumour stem cell assay. Pathol. Biol. 36:1988;83.
20. Shepherd F. A. Screening diagnosis and staging of lug cancer. Curr. Opin. Oncol. 5:1993;310.
21. Feld R., Sagman U., LeBlanc M. Staging and prognostic factors Small cell lung cancer . Pass H. I., Mitchell J. B., Johnson D. H., Turrisi A. T. Lung cancer Principles and practice . 1997;495-509 Lippincott-Raven Publishers, Philadelphia, PA.
22. Kaplan E. L., Meier F. Nonparametric estimation form incomplete observations. J. Am. Stat. Assoc. 58:1958;457-481.
23. Aisner J., Goutsou M., Maurer L. H., et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer A Cancer and Leukemia Group B pilot study . J. Clin. Oncol. 10:1992;1230-1236.
24. Johnson B. E., Bridges J. D., Sobczeck M., et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J. Clin. Oncol. 14:1996;806-813.
25. Johnson D. H., Turrisi A. T., Chang A. Y., et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer A pilot study of the Eastern Cooperative Oncology Group . J. Clin. Oncol. 11:1993;879-884.
26. Johnson D. H., Bass D., Einhorn L. H., et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer A randomized trial of the Southeastern Cancer Study Group . J. Clin. Oncol. 11:1993;1223-1229.
27. Kwiatkowski D. J., Prospect K. J., Carey R. W., et al. A phase II trial of cyclophosphamide, etoposide, and cisplatin, with combined chest and brain radiotherapy in limited small-cell lung cancer A Cancer and Leukemia Group B study . J. Clin. Oncol. 5:1987;1874-1879.
28. Perry M. C., Eaton W. L., Propert K. J., et al. Chmotherapy with or without radiation therapy in limited stage small cell carcinoma of the lung. N. Engl. J. Med. 316:1987;912-918.
29. Dajczman E., Hanley J., Lisbona A., et al. Comparison or response evaluation in small cell lung cancer using computerized tomography and chest radiography. Lung Cancer. 11:1994;51-60.
30. Lee J. S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable nonsmall-cell lung cancer Radiation Therapy Oncology Group protocol 91-06 . J. Clin. Oncol. 14:1996;1055-1064.
31. Brooks B. J., Seifter E. J., Walsh T. E., et al. Pulmonary toxicity with combined modality therapy for limited-stage small-cell cancer. J. Clin. Oncol. 4:1986;200-209.
32. Roach M. III, Gandara D. R., Yuo H.-S., et al. Radiation pneumonitis following combined modality therapy for lung cancer Analysis of prognostic factors . J. Clin. Oncol. 13:1995;2606-2612.
33. Schiller J. H., Ettinger D. S., Larson M. M., et al. Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung An Eastern Cooperative Oncology Group study . Eur. J. Cancer. 30A:1994;158-161.
34. D'Incalci M., Farina P., Sessa C., et al. Pharmacokinetics of ETOPOSIDE-213 given by different administration methods. Cancer Chemother. Pharmacol. 7:1982;141-154.
35. Smyth R. D., Pfeffer M., Scalzo A., et al. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin. Oncol. 12:(Suppl. 2):1985;48-51.
36. Stewart D. J., Nundy D., Maroun J. A., et al. Bioavailability, pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat. Rep. 69:1985;269-273.
37. Carney D. N. The pharmacology of intravenous and oral etoposide. Cancer. 67:1991;299-302.
38. Cunningham D., McTaggart L., Soukop M., et al. Etoposide A pharmacokinetic profile including an assessment of bioavailability . Med. Oncol. Tumor Pharmacother. 3:1986;95-99.
39. Fujiwara Y., Ohune T., Okusaki K., et al. Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. Cancer Chemother. Pharmacol. 37:1996;327-331.
40. Hande K. R., Krozely M. G., Greco F. A., et al. Bioavailability of low-dose oral etoposide. J. Clin. Oncol. 11:1993;374-377.
41. Harvey V. J., Slevin M. L., Joel S. P., et al. Variable bioavailability folowing repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol. 21:1985;1315-1319.
42. Sessa C., Zucchetti M., Cerny T., et al. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J. Clin. Oncol. 13:1995;200-209.
43. Slevin M. L., Joel S. P., Whomsley R., et al. The effect of dose on the bioavailability of oral etoposide Confirmation of a clinically relevant observation . Cancer Chemother. Pharmacol. 24:1989;329-331.
44. Clark P. I., Slevin M. L., Joel S. P., et al. A randomized trial of two etoposide schedules in small-cell lung cancer The influence of pharmacokinetics on efficacy and toxicity . J. Clin. Oncol. 12:1994;1427-1435.
45. Minami H., Ando Y., Sakai S., et al. Clinical and pharmacological analysis of hyperfractionated daily oral etoposide. J. Clin. Oncol. 13:1995;191-199.
46. Waits T. M., Johnson D. H., Hainsworth J. D., et al. Prolonged administration of oral etoposide in nonsmall cell lung cancer A phase II trial . J. Clin. Oncol. 10:1992;292-296.
47. Joel S. P., Clark P. I., Heap L., et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother. Pharmacol. 37:1995;125-133.
48. Schiller J. H., Kim K. M., Hutson P., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung An Eastern Cooperative Oncology Group trial . J. Clin. Oncol. 14:1996;2345-2352.
49. Miller AA, Herdon JE, Hollis DR, et al: Schedule dependency of 21-day oral vs. 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13:1871-1879, 1995.